New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:38 EDTADXS, PETXAdvaxis files for USDA product license
Advaxis (ADXS) announced that a product license from the USDA has been filed for ADXS-cHER2, its proprietary Her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other HER2-overexpressing cancers. The filing was submitted by Aratana Therapeutics (PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize ADXS-cHER2 in animals. While the USDA has no specific obligation to respond within a prescribed timeframe, the companies expect a response from the USDA to the filing will occur over the next 12 to 18 months.
News For ADXS;PETX From The Last 14 Days
Check below for free stories on ADXS;PETX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:22 EDTPETXAratana Therapeutics 4.5M share Spot Secondary priced at $9.25
Subscribe for More Information
September 16, 2014
18:30 EDTPETXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee Enterprises (APOG), up 5.6% after reporting second quarter results and raising fiscal 2015 guidance. ALSO HIGHER: InspireMD (NSPR), up 18.5% after reporting positive trial results for CGuard... Boeing (BA), up marginally after NASA awarded the company with a $4.2B contract for commercial spaceflight to the International Space Station... U.S. Steel (X), up 7.9%% after updating third quarter outlook. DOWN AFTER EARNINGS: Adobe (ADBE), down 4.5% following third quarter results. ALSO LOWER: Rackspace Hosting (RAX), down 16.7% after ending strategic review and deciding to stay independent... Sunoco Logistics Partners (SXL), down 3.9% after filing to sell 7.7M shares of common stock... Aratana Therapeutics (PETX), down 7.8% after filing to sell common stock.
16:01 EDTPETXAratana Therapeutics files to sell common stock, no amount given
Subscribe for More Information
September 9, 2014
07:43 EDTADXSAdvaxis provides clinical development updatefor ADXS-HPV
Subscribe for More Information
07:05 EDTPETXAratana Therapeutics announces positive results from AT-003 field study
Aratana Therapeutics announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension, or AT-003, for managing post-operative pain in cats and dogs following surgery. In the study, which enrolled 46 client-owned dogs, AT-003 demonstrated significantly greater pain control over time following knee surgery compared to placebo. Based on these results, Aratana anticipates discussing the design of the pivotal field effectiveness with the FDA in the coming weeks and continues to anticipate the first FDA approval in 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use